Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference

September 30, 2019

LAWRENCEVILLE, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- **Celsion Corporation** **(NASDAQ: CLSN)**, an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief Executive Officer and Khursheed Anwer, Executive Vice President and Chief Scientific Officer will present at the Chardan 3rd Annual Genetic Medicines Conference on Monday, October 7, 2019 at 9:00 a.m. Eastern time. Management's participation will take the form of a "Fireside Chat" and will primarily focus on the Company's development program for GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. The conference is being held at the Westin New York Grand Central Hotel in New York City from October 7 - 8.

A webcast of Celsion's discussion may be accessed by visiting the "News & Investors" section of Celsion's corporate website at www.celsion.com.

About Celsion Corporation

Celsion is a fully integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox ®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company's product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies.

Forward-looking Statements

Forward-looking statements in this news release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in the Celsion's periodic filings with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Celsion Investor Contact

Jeffrey W. Church
Executive Vice President and CFO
609-482-2455
jchurch@celsion.com

Or

LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

# # #

Source: Celsion CORP